Clinical trials: Metastatic Lung Non-Small Cell Carcinoma
Non-Small Cell Lung Cancer
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare the efficacy and toxicity of pemetrexed and docetaxel administered on a 3-weekly schedule in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00391274
- Testing
- pemetrexed, docetaxel
- Where
- 7 sites in China
- Volunteers
- 211 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Cancer
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- Trial name
- KYLIN-2 (NCT06574347)
- Testing
- Vebreltinib, Osimertinib, PLB1004
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Avistone Biotechnology Co., Ltd.
Advanced Non-Small Cell Lung Cancer
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.
- Trial name
- NCT05504278
- Testing
- IBI351, Cetuximab, pemetrexed
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
ALK-positive Non-small Cell Lung Cancer, Real World Study
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI…
- Trial name
- NCT06361589
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Non Small Cell Lung Cancer Metastatic
Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases
With the improvement of systemic therapeutic effect(especially in the population with driver gene mutation), the incidence of brain metastases had significantly increased.
- Trial name
- NCT03732482
- Testing
- Temozolomide capsules, radiotherapy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Taizhou Hospital
Lung Cancer
Beta-Glucan in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Biological therapies, such as beta-glucan, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00857025
- Testing
- beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.
- Trial name
- NCT07034391
- Testing
- denosumab combined anti-PD-1 inhibitor with chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- China Medical University, China
Metastatic Non-small Cell Lung Cancer, Neoplasm
Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study
This retrospective, single-center observational cohort study evaluates inflammatory-metabolic, cachexia-related, and computed tomography (CT)-derived body-composition markers in patients with metastatic non-small cell lung cancer…
- Trial name
- SARC-CTI (NCT07192926)
- Testing
- Immune Checkpoint Inhibitor-Based Therapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 155 people
- Sponsor
- Ankara Etlik City Hospital
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT00021060
- Testing
- paclitaxel, carboplatin, bevacizumab
- Where
- United States
- Volunteers
- 842 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
The study will take place over a period of 27 months. The recruitment phase will last approximately 24 months and each patient will participate for approximately 3 months.
- Trial name
- NCT02483416
- Where
- 36 sites in France
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer, Non Small Cell Lung Cancer
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer
- Trial name
- NCT03177291
- Testing
- Pirfenidone, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced or Metastatic NSCLC
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung…
- Trial name
- NCT04526691
- Testing
- Datopotamab deruxtecan, KEYTRUDA®, Carboplatin
- Where
- 24 sites in United States, Italy and 3 more
- Volunteers
- 145 people
- Sponsor
- Daiichi Sankyo
Metastatic Nonsmall Cell Lung Cancer
Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer
The study aims include: Exploring potential predictive molecular profiles to immunotherapy/chemotherapy Investigating the role of circulating tumor DNA as a dynamic biomarker during immunotherapy/chemotherapy Identifying possible…
- Trial name
- NCT03512847
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Zealand University Hospital
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the…
- Trial name
- FORTIS-C (NCT00706862)
- Testing
- Talactoferrin
- Where
- 6 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Agennix
Carcinoma, Non-Small-Cell Lung
Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
The purpose of this trial was to evaluate the safety and efficacy of capmatinib in combination with spartalizumab in adult participants with epidermal growth factor receptor (EGFR) wild type (for exon 19 deletions and exon 21…
- Trial name
- NCT03647488
- Testing
- Capmatinib, Spartalizumab, Docetaxel
- Where
- 8 sites in United States, Belgium and 4 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Non-small Cell Lung Cancer
Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer
The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to…
- Trial name
- NCT00806286
- Testing
- CS7017 tablets, Paclitaxel, Carboplatin
- Where
- 28 sites in United States, India and 2 more
- Volunteers
- 111 people
- Sponsor
- Daiichi Sankyo
Advanced or Metastatic NSCLC
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
this is a phase I study comparing PK similarity of sintilimab by different production process (approved versus M1b) in Chinese advanced or metastatic NSCLC patients who have failed or been intolerant to at least one prior line of…
- Trial name
- NCT04177290
- Testing
- Sintilimab (M1b), Sintilimab (approved)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
At present, it is recommended to continue immunotherapy until progression or unacceptable toxicity. However, only a minority of patients benefits from a durable response and most see the disease progress despite several months of…
- Trial name
- TRAILOCLORI01 (NCT05111197)
- Testing
- SRT, Immunotherapy
- Where
- 5 sites in France
- Volunteers
- 112 people
- Sponsor
- Institut Cancerologie de l'Ouest
Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced…
- Trial name
- FINN (NCT06487156)
- Testing
- Nivolumab + ipilimumab
- Where
- Italy
- Volunteers
- 404 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.